Drug interaction between St John's wort and zolpidem in healthy subjects

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 6, 2011, Pages 711-715

  Hojo, Y ^a   Echizenya, M ^a   Ohkubo, T ^b   Shimizu, T ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Research Institute of Shichifuku Pharmacy   (Japan)

Author keywords

CYP3A4; drug interaction; personalized medicine; St John's wort; zolpidem

Indexed keywords

ZOLPIDEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; HYPERICUM; HYPNOTICS AND SEDATIVES; MALE; PLANT EXTRACTS; PYRIDINES; YOUNG ADULT;

EID: 80055061104     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01223.x     Document Type: Article

References (22)

1. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D, (1996) St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ, 313, 253-258. (Pubitemid 26254730)
2. Durr D, Stieger B, Kullak-Ublick GA, et al. (2000) St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clinical Pharmacology and Therapeutics, 68, 598-604. (Pubitemid 32059985)
3. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH, (2000) St John's Wort: effect on CYP3A4 activity. Clinical Pharmacology and Therapeutics, 67, 451-457. (Pubitemid 30327483)
4. Jiang X, Williams KM, Liauw WS, et al. (2004) Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 57, 592-599. (Pubitemid 38582179)
5. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I, (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics, 66, 338-345. (Pubitemid 29494126)
6. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G, (2000) Acute heart transplant rejection due to Saint John's wort. Lancet, 355, 548-549. (Pubitemid 30088678)
7. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J, (2000) Indinavir concentrations and St John's wort. Lancet, 355, 547-548. (Pubitemid 30088677)
8. Johne A, Schmider J, Brockmoller J, et al. (2002) Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John's wort (Hypericum perforatum). Journal of Clinical Psychopharmacology, 22, 46-54. (Pubitemid 34101292)
9. de Maat MM, Hoetelmans RM, Math t RA, et al. (2001) Drug interaction between St John's wort and nevirapine. AIDS, 15, 420-421. (Pubitemid 32163832)
10. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB, (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics, 73, 41-50. (Pubitemid 36158485)
11. Markowitz JS, Donovan JL, DeVane CL, et al. (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA, 290, 1500-1504. (Pubitemid 37430406)
12. Staner L, (2010) Comorbidity of insomnia and depression. Sleep Medicine Reviews, 14, 35-46.
13. Kawaguchi A, Ohmori M, Tsuruoka S, et al. (2004) Drug interaction between St John's Wort and quazepam. British Journal of Clinical Pharmacology, 58, 403-410. (Pubitemid 39312464)
14. Dennis T, Dubois A, Benavides J, Scatton B, (1988) Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain: an autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem. Journal of Pharmacology and Experimental Therapeutics, 247, 309-322.
15. Von Moltke LL, Greenblatt DJ, Granda BW, et al. (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology, 48, 89-97. (Pubitemid 29296668)
16. Kudo M, Ohkubo T, Sugawara K, (1999) Determination of sparfloxacin in plasma by direct injection high performance liquid chromatography with column switching. Journal of Liquid Chromatography & Related Technologies, 22, 441-449. (Pubitemid 29102731)
17. Ohkubo T, Kudo M, Sugawara K, (1992) Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. Journal of Chromatography, 573, 289-293.
18. Rengelshausen J, Banfield M, Riedel KD, et al. (2005) Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clinical Pharmacology and Therapeutics, 78, 25-33. (Pubitemid 40956928)
19. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P, (1995) Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 23, 1253-1262.
20. Wang LS, Zhu B, Abd El-Aty AM, et al. (2004) The influence of St John's Wort on CYP2C19 activity with respect to genotype. Journal of Clinical Pharmacology, 44, 577-581. (Pubitemid 38668019)
21. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD, (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics, 70, 317-326. (Pubitemid 33022472)
22. Greenblatt DJ, Harmatz JS, Von Moltke LL, et al. (1998) Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clinical Pharmacology and Therapeutics, 64, 553-561. (Pubitemid 28531600)